Zolbetuximab
Based on 4 publication(s) in Google Scholar
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
For research use only. We do not sell to patients.
- Purity: 98.03%
- CAS No.: 1496553-00-4
- Molecular Weight:147.09 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Zolbetuximab
More-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
Biological Activity
Human IgG1 kappa
Human
CLDN18.2
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2]
-
Dosage:200 μg alone or with 50 mg/kg Gemcitabine
-
Administration:i.v.; i.p. (Gemcitabine)
-
Result:Inhibited tumor growth in two models, and prevented lung metastasis formation.
Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Claudin-18/CLDN18.2 Protein-VLP, Human (HEK293, HY-P78368) can bind Zolbetuximab. The EC50 for this effect is 6.588 ng/mL.
Chemical Information
-
CAS No. 1496553-00-4
-
Appearance Liquid
-
Molecular Weight 147.09 kDa
-
Color Colorless to light yellow
-
SMILES
[Zolbetuximab]
-
Synonyms
IMAB362; Claudiximab; GC-182
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Commun Signal
Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. [Abstract]2024 Jan 10;22(1):27. PMID: 38200591 -
Cell Rep
2025 Aug 21;44(9):116191. PMID: 40848256
Zolbetuximab purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Aug 21;44(9):116191. [Abstract]
Zolbetuximab (0.01-100 nM). Dose-response curves of PDAC organoids in cell surface target-specific cytoablation assay. Data are representative of three biological replicates and are shown as mean ± SD.
-
Mol Cancer Ther
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. [Abstract]2023 Dec 1;22(12):1365-1375. PMID: 37788341 -
Heliyon
A novel highly sensitive inner filter effect-based fluorescence immunoassay with quantum dots for bioanalysis of zolbetuximab, a monoclonal antibody used for immunotherapy of gastric and gastroesophageal junction adenocarcinoma. [Abstract]2024 Jul 14;10(14):e34611. PMID: 39114008
Zolbetuximab purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Jul 14;10(14):e34611. [Abstract]
The titration of varying concentrations of CLDN 18.2 protein versus a fixed high concentration of Zolbetuximab (ZOL, 2 μg/mL).
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080. [Content Brief]
[2]. Türeci Ӧ, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096. [Content Brief]
[3]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)